During Friday’s trade, Shares of Sunedison Inc (NYSE:SUNE), gain 2.93% to $4.21, after the company declared that it sold wind-power assets to Terra Nova Renewable Partners for $209 million.
Based in Saint Peters, MO, SunEdison is a clean power energy development company. Terra Nova is a planned equity partnership formed in September by SunEdison and investors advised by JPMorgan Chase & Co.’s Asset Administration.
The partnership enables JPMorgan’s clients to provide equity to purchase SunEdison’s renewable energy projects.
“This transaction represents good value for SunEdison’s shareholders and enhances our financial strength and flexibility,” SunEdison CFO Brian Wuebbels said in a statement on Thursday. “Terra Nova’s purchase is representative of the strong demand we’ve seen for ownership of SunEdison’s attractive renewable energy assets.”
SunEdison, Inc. (SunEdison) is a developer and seller of photovoltaic energy solutions, an owner and operator of clean power generation assets, and a developer and manufacturer of silicon wafers. The Company operates in three segments: Solar Energy, TerraForm Power and Semiconductor Materials through SunEdison Semiconductor Ltd. (SSL).
Shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), declined -4.49% to $4.47, during its current trading session.
On December 9, Aeterna Zentaris Inc. (AEZS) (AEZ.TO) declared the pricing of its formerly declared underwritten public offering (the “Offering”) of common shares and warrants with a public offering price of US$5.55 for one common share together with a warrant to purchase 0.7 of a common share for gross proceeds of US$16.65 million. A total of 3.0 million common shares and warrants to acquire 2.1 million common shares are predictable to be issued on closing of the Offering. In addition, the Company has granted the underwriter a 45-day option to purchase up to an additional 330,000 common shares and/or warrants to purchase up to an additional 231,000 common shares, to cover over-allotments, if any.
The warrants will be exercisable right away and expire five years following issuance at an exercise price of US$7.10 per share. The warrants do not contain any price or other adjustment provision, except for customary adjustment provisions that apply in the event of certain corporate events or transactions that affect all outstanding common shares. The warrants may at any time be exercised on a “net” or “cashless” basis in accordance with a customary formula but do not contain an alternate cashless exercise feature contained in our formerly issued Series B common shares purchase warrants. The warrants will not be listed on any stock exchange.
On the other news report, on December 8, Aeterna Zentaris Inc. (AEZS) (AEZ.TO) declared that on December 7, 2015, NASDAQ notified the Company that it has regained compliance with Rule 5450(a)(1), which requires a minimum bid price of $1.00 for continued listing on the NASDAQ Capital Market.
Commenting on the declaration, David A. Dodd, Chairman, President and Chief Executive Officer of the Company, stated: “We are happy that we have been able to regain compliance with NASDAQ’s minimum bid price rule, because our NASDAQ listing is important in maintaining liquidity in the trading of our common shares.”
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and women’s health. The Company has three wholly owned direct and indirect auxiliaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned partner of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc.
Finally, Shares of Great Basin Scientific Inc (NASDAQ:GBSN), lost -19.77%, and is now trading at $0.106.
Great Basin Scientific, Inc. (GBSN), a molecular diagnostics company, declared that a 1-for-60 reverse split of its common stock will be effective at 5:00 pm EST on December 11, 2015. The Company’s common stock will open for trading on the Nasdaq Capital Market on Monday, December 14, 2015 on a post-split basis. At the effective time of the reverse stock split, every 60 shares of the Company’s issued and outstanding common stock, par value $0.001, will be merged into 1 newly issued and outstanding share of common stock, par value of $0.0001.
Great Basin Scientific, Inc. is a molecular diagnostic testing company. The Company is focused on the development and commercialization of its molecular diagnostic platform designed to test for infectious disease. The Company has a commercially available test, a diagnostic test for clostridium difficile (C. diff), which received clearance from the Food and Drug Administration (FDA).